FDA Approved Drugs by Medical Condition

Search by medical condition for drugs approved by the Food and Drug Administration (FDA) for sale in the United States. Select the letter below that corresponds to the first letter of the medical condition you are searching for and all approved drugs classified under that category will be listed below.

Kaposi's Sarcoma

Taxol (by Bristol-Myers Squibb), Approved August 1997
Treatment for AIDS-related Kaposi's Sarcoma

Keratoses

Ameluz (aminolevulinic acid hydrochloride) (by Biofrontera Pharma), Approved May 2016
For the treatment of actinic keratoses

Picato (ingenol mebutate) gel (by LEO Pharma), Approved January 2012
For the treatment of actinic keratosis

Zyclara (imiquimod) (by Graceway), Approved March 2010
For the treatment of actinic keratoses of the face and scalp

Kidney Cancer

Inlyta (axitinib) (by Pfizer), Approved January 2012
For the treatment of advanced renal cell carcinoma

Lenvima (lenvatinib) (by Eisai), Approved May 2016
For the treatment of advanced renal cell carcinoma

Opdivo (nivolumab) (by Bristol-Myers Squibb), Approved November 2015
For the treatment of advanced renal cell carcinoma

Kidney Disease

Auryxia (Ferric citrate) (by Keryx Biopharma), Approved September 2014
For the treatment of hyperphosphatemia in patients with chronic kidney disease

Injectafer (ferric carboxymaltose injection) (by Luitpold Pharmaceuticals), Approved July 2013
For the treatment of iron deficiency anemia

Nulojix (belatacept) (by Bristol-Myers Squibb), Approved June 2011
For the prevention of organ rejection following kidney transplant

Omontys (peginesatide) (by Affymax), Approved March 2012
For the treatment of anemia due to chronic kidney disease

Parsabiv (etelcalcetide) (by Amgen), Approved February 2017
For the treatment of secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis

Procysbi (cysteamine bitartrate) (by Raptor Pharmaceuticals), Approved May 2013
For the management of nephropathic cystinosis

Rayaldee (calcifediol) (by Opko Health), Approved June 2016
For the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease

Renagel (sevelamer hydrochloride) (by Genzyme), Approved July of 2000
For the control of serum phosphorus in patients with chronic kidney disease on dialysis

Renvela (sevelamer carbonate) (by Genzyme), Approved October 2007
For the control of serum phosphorus in patients with chronic kidney disease on dialysis

Voraxaze (glucarpidase) (by BTG International), Approved January 2012
For the treatment of toxic plasma methotrexate concentrations in patients with impaired renal function

Kidney Failure

Auryxia (Ferric citrate) (by Keryx Biopharma), Approved September 2014
For the treatment of hyperphosphatemia in patients with chronic kidney disease

Soliris (eculizumab) (by Alexion), Approved March 2007
For the treatment of paroxysmal nocturnal hemoglobinuria

Soliris (eculizumab) (by Alexion), Approved September 2011
For the treatment of atypical hemolytic uremic syndrome

Voraxaze (glucarpidase) (by BTG International), Approved January 2012
For the treatment of toxic plasma methotrexate concentrations in patients with impaired renal function

Kidney Failure (Pediatric)

Soliris (eculizumab) (by Alexion), Approved March 2007
For the treatment of paroxysmal nocturnal hemoglobinuria

Soliris (eculizumab) (by Alexion), Approved September 2011
For the treatment of atypical hemolytic uremic syndrome

Kidney Transplantation

Envarsus XR (tacrolimus extended-release) (by Veloxis), Approved July 2015
For the prophylaxis of organ rejection in kidney transplant patients

Nulojix (belatacept) (by Bristol-Myers Squibb), Approved June 2011
For the prevention of organ rejection following kidney transplant

Prograf (by Fujisawa Healthcare), Approved April 1997
Treatment for the prevention of kidney transplant rejection

Rapamune (sirolimus) Tablets (by Wyeth), Approved August 2000
For treatment of kidney rejection

Zenapax (by Roche), Approved December 1997
Treatment to prevent rejection of kidney transplants

Zortress (everolimus) (by Novartis), Approved May 2010
For the prevention of organ rejection following kidney transplant